{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-117179","form_type":"8-K","ticker":"ATXI","cik":"0001644963","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.551746+00:00","generated_at":"2026-06-21T23:06:00.251456+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Avenue Therapeutics reports Q3 net loss $0.7M; FDA meeting on IV Tramadol and acquisition of Baergic Bio","bullets":["Q3 2022 net loss $0.7M ($0.45/share) vs $0.9M ($0.79/share) in Q3 2021.","Cash $0.2M at Sep 30, 2022 (down from $3.8M at Dec 31, 2021); then raised ~$10.4M net in October offering.","FDA agreed proposed IV Tramadol study design appears reasonable; detailed protocol submission planned.","Completed acquisition of Baergic Bio, adding BAER-101 (GABA-A α2/3 PAM) for refractory epilepsies and panic disorders.","Effected 1-for-15 reverse stock split and closed $12M public offering; regained Nasdaq compliance."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-117179","json":"https://secwatch.observer/filing/0001104659-22-117179.json","markdown":"https://secwatch.observer/filing/0001104659-22-117179.md","text":"https://secwatch.observer/filing/0001104659-22-117179.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1644963/000110465922117179/0001104659-22-117179-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1644963/000110465922117179/tm2230162d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T23:06:00.251456+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b723f4ef1ec72557ecb6bab6ebd8a67b89373ca8","claim":"AVENUE THERAPEUTICS, INC. reported the third quarter ended September 30, 2022 results: net income Net loss attributable to common stockholders for the third quarter of 2022 was $0.7 million, or $0.45 per share.","evidence_excerpt":"Avenue Therapeutics, Inc. (the “Company” or “Avenue”) issued a press release to provide a corporate update and to announce its financial results for the three months ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1644963/000110465922117179/0001104659-22-117179-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Net income","value":"Net loss attributable to common stockholders for the third quarter of 2022 was $0.7 million, or $0.45 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}